Biomedical application of chitosan-based nanoscale delivery systems: Potential usefulness in siRNA delivery for cancer therapy
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Review
PubMed
33712155
DOI
10.1016/j.carbpol.2021.117809
PII: S0144-8617(21)00196-X
Knihovny.cz E-resources
- Keywords
- Cancer therapy, Chitosan, Gene delivery, Nanoparticle, Small interfering RNA (siRNA),
- MeSH
- Drug Resistance, Neoplasm drug effects MeSH
- Chitosan chemistry MeSH
- Humans MeSH
- RNA, Small Interfering chemistry therapeutic use MeSH
- Neoplasms drug therapy pathology therapy MeSH
- Nanoparticles chemistry MeSH
- Drug Carriers chemistry MeSH
- Antineoplastic Agents chemistry pharmacology therapeutic use MeSH
- Gene Silencing MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Chitosan MeSH
- RNA, Small Interfering MeSH
- Drug Carriers MeSH
- Antineoplastic Agents MeSH
Gene therapy is an emerging and promising strategy in cancer therapy where small interfering RNA (siRNA) system has been deployed for down-regulation of targeted gene and subsequent inhibition in cancer progression; some issues with siRNA, however, linger namely, its off-targeting property and degradation by enzymes. Nanoparticles can be applied for the encapsulation of siRNA thus enhancing its efficacy in gene silencing where chitosan (CS), a linear alkaline polysaccharide derived from chitin, with superb properties such as biodegradability, biocompatibility, stability and solubility, can play a vital role. Herein, the potential of CS nanoparticles has been discussed for the delivery of siRNA in cancer therapy; proliferation, metastasis and chemoresistance are suppressed by siRNA-loaded CS nanoparticles, especially the usage of pH-sensitive CS nanoparticles. CS nanoparticles can provide a platform for the co-delivery of siRNA and anti-tumor agents with their enhanced stability via chemical modifications. As pre-clinical experiments are in agreement with potential of CS-based nanoparticles for siRNA delivery, and these carriers possess biocompatibiliy and are safe, further studies can focus on evaluating their utilization in cancer patients.
Centre for Materials Interface Istituto Italiano di Tecnologia Pontedera 56025 Pisa Italy
Sabanci University Nanotechnology Research and Application Center Tuzla 34956 Istanbul Turkey
Young Researchers and Elite Club Tehran Medical Sciences Islamic Azad University Tehran Iran
References provided by Crossref.org
Gene Editing-Based Technologies for Beta-hemoglobinopathies Treatment
